OraSure Technologies, Inc. (NASDAQ:OSUR) SVP Jack E. Jerrett sold 73,463 shares of OraSure Technologies stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $20.77, for a total transaction of $1,525,826.51. Following the sale, the senior vice president now owns 81,593 shares in the company, valued at $1,694,686.61. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

OraSure Technologies, Inc. (NASDAQ OSUR) opened at 21.46 on Wednesday. OraSure Technologies, Inc. has a 12 month low of $6.84 and a 12 month high of $21.55. The company has a market capitalization of $1.25 billion, a PE ratio of 39.67 and a beta of 1.57. The firm’s 50-day moving average is $17.63 and its 200-day moving average is $13.64.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.02. The business had revenue of $40.18 million for the quarter, compared to analysts’ expectations of $36.54 million. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.07 EPS. Equities analysts anticipate that OraSure Technologies, Inc. will post $0.48 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “OraSure Technologies, Inc. (OSUR) SVP Sells $1,525,826.51 in Stock” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/08/09/orasure-technologies-inc-osur-svp-sells-1525826-51-in-stock.html.

A number of research analysts have recently issued reports on OSUR shares. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Saturday, May 6th. Jefferies Group LLC boosted their price target on shares of OraSure Technologies from $12.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, May 4th. Canaccord Genuity boosted their price target on shares of OraSure Technologies from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, June 28th. Stephens restated an “overweight” rating and set a $19.00 price target (up previously from $14.00) on shares of OraSure Technologies in a research note on Tuesday, July 11th. Finally, BidaskClub lowered shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $15.46.

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its position in shares of OraSure Technologies by 127,593.4% in the first quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock valued at $100,123,000 after buying an additional 7,737,261 shares during the period. Norges Bank bought a new stake in shares of OraSure Technologies during the fourth quarter worth $9,786,000. Vanguard Group Inc. boosted its stake in shares of OraSure Technologies by 30.3% in the first quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock worth $57,752,000 after buying an additional 1,037,439 shares during the period. Renaissance Technologies LLC boosted its stake in shares of OraSure Technologies by 22.3% in the first quarter. Renaissance Technologies LLC now owns 5,132,003 shares of the medical instruments supplier’s stock worth $66,357,000 after buying an additional 934,700 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of OraSure Technologies by 127.2% in the first quarter. JPMorgan Chase & Co. now owns 1,573,586 shares of the medical instruments supplier’s stock worth $20,347,000 after buying an additional 881,132 shares during the period. 90.12% of the stock is currently owned by institutional investors.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.